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a b s t r a c t
Background: In acutely decompensated heart failure (ADHF) patient's higher aldosterone
levels correlate with worse postdischarge outcomes, suggesting that further modulation of
the mineralocorticoid system during or immediately after hospitalization might favorably
improve outcomes.
Methods and results: This was an observational, retrospective secondary analysis of a study
including 100 patients with ADHF. In that study 50 patients were submitted to spironolac-
tone treatment (50–100 mg/day). A higher proportion of patients with renin levels above
16.5 pg/mL and aldosterone levels above 100 ng/dL were observed in subjects submitted to
spironolactone treatment (44.7% vs. 66.7% and 56% vs. 64.7%, respectively, both p < 0.05). In
the group of patients submitted to spironolactone treatment the proportion of patients with
renin and aldosterone levels above the cutoff had a signiﬁcant increase from baseline to day
3 (24–32% and 16–44%, respectively, both p < 0.05). Log renin and aldosterone were higher in
patients with renin and aldosterone levels above the cutoff point (both p < 0.05).
Conclusions: High-dose spironolactone added to standard ADHF therapy induces an addi-
tional increase in renin and aldosterone levels. Whether higher levels of renin and aldoste-
rone due to the reactive response to full MRA still have prognostic value requires further
investigation.
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The use of mineralocorticoid receptor antagonists (MRAs) has
demonstrated to improve outcomes and reduce mortality in
chronic heart failure (HF) and postmyocardial infarction [1–3].
The beneﬁt observed with MRAs is probably due to the
excessive neurohormonal activation blockade.
Particularly, aldosterone is probably essential for the
progression of HF. Higher aldosterone levels were found in
patients with chronic HF when compared with controls, and
were found to be associated with poor outcome [4–7]. A rise in
aldosterone levels was also observed in the acute myocardial
infarction setting [8,9], and likewise associated with worse
outcomes in this setting [10].
In acutely decompensated heart failure (ADHF) patients
with ejection fraction (EF) <40%, higher aldosterone levels
correlate with worse postdischarge outcomes [11], suggest-
ing that further modulation of the mineralocorticoid system
during or immediately after hospitalization might favorably
improve outcomes. Regarding this matter, high dose
spironolactone as add-on therapy in the acutely decom-
pensated heart failure (ADHF) setting has been demonstrat-
ed to be safe and likely to provide greater symptomatic relief
translated into a more pronounced decrease in natriuretic
peptides [12].
We used an ADHF model to study the inﬂuence of the MRA
spironolactone on renin and aldosterone. The aim of this
study is to demonstrate the renin and aldosterone associa-
tions and changes before and after the spironolactone
introduction.
Methods
Study design
This study is based on analyzed data from a previous
prospective, interventional, clinical trial that we performed
[12]. In that study we enrolled 100 consecutive patients who
presented in a Portuguese tertiary hospital with ADHF,
between February 2012 and February 2013. They were
nonrandomly assigned in a sequential 1:1 ratio to spirono-
lactone plus standard ADHF therapy or standard ADHF
therapy alone, 50 patients within each arm (i.e. patients were
alternatively assigned to spironolactone arm or standard
ADHF therapy arm in a sequential manner – the ﬁrst patient to
one arm and the next patient to the other arm. This sequence
was repeated until we reach 100 patients, 50 patients within
spironolactone group and 50 patients within control group.
Patients were blinded to the allocation, and the clinicians were
not blinded to the allocation. The recommended spironolac-
tone dose was 100 mg/day; however, the assistant physician
could decrease the spironolactone dose to 50 mg/day after 48 h
upon admission. After 72 h the study was open label.
Furosemide dose and form of administration were performed
according to the treating physician.
Patients were eligible for enrollment if they presented with
decompensation of chronic HF with symptoms leading to
hospitalization. All patients presented at the emergencydepartment severely symptomatic in NYHA class IV. ADHF
was diagnosed on the basis of the presence of history of
chronic HF, at least one symptom (dyspnea, orthopnea, or
edema), one sign (rales, peripheral edema, ascites, or
pulmonary vascular congestion on chest radiography) and
elevated natriuretic peptides. Exclusion criteria were: chronic
use of MRAs, cardiac surgery within 60 days of enrollment,
cardiac mechanical support, cardiac resynchronization ther-
apy within the last 60 days, comorbid conditions with an
expected survival of less than 6 months, acute MI at time of
hospitalization, hemodynamically signiﬁcant uncorrected
primary cardiac valvular disease, patients requiring intrave-
nous vasodilators or inotropic agents, supine systolic arterial
blood pressure <90 mmHg, plasma creatinine (pCr) level
>1.5 mg/dL, serum potassium level >5.0 mmol/L, hemoglobin
(HgB) level <9 g/dL, and sepsis.
Institutional review board or ethics committee approval
was obtained. All the patients provided written informed
consent to participate in the study.
Study assessments
Patient's clinical status including physical examination was
prospectively recorded by the same assistant physician at day
1 and day 3.
Medications and respective dosages were prospectively
recorded by the investigators according to the assistant
physician prescriptions.
Blood and spot urine samples were collected in the ﬁrst
24 hours (h) after admission (day 1) of the patient to the
hospital. The ﬁrst dose of spironolactone was only adminis-
tered after the ﬁrst sample was collected. Fifty patients had
daily oral spironolactone according to the study protocol
described above. The day 3 samples were collected between 72
and 96 h of hospitalization. All the samples were collected in
the morning with the patient in supine position, and ﬁrst-
morning spot urine was used. All the patients had low-salt,
low-calorie hospital diet. Extra fruit and vegetables adminis-
tration was not allowed. An assessment of biomarkers
(including pCr, plasma urea [pUr], electrolytes, N-terminal
pro-brain natriuretic peptide [NTproBNP], high-sensitivity
troponin T [hsTnT], and proteinuria) was performed at a
central core laboratory at day 1 and day 3. Clinical assessment
and routine analyses were performed daily during hospital
stay. A transthoracic echocardiography was performed on all
the patients within 72 h upon admission. Left ventricle
ejection fraction (LVEF) was calculated according to the
biplane Simpson method.
Aldosterone was measured using radioimmunoassay (RIA)
Coat-a-Count® (Siemens) and renin with RIA (DiaSource®).
Variable deﬁnitions
We deﬁned high renin levels when values were above the
16.5 pg/mL cutoff, and high aldosterone levels when values
were above the 100 ng/dL cutoff. The manufacturer suggested
a cutoff of 16.5 pg/mL for renin and a cutoff of 160 ng/dL for
aldosterone. We lowered aldosterone cutoff to 100 ng/dL to
increase test sensitivity, although levels above 160 ng/dL are
more speciﬁc, we might miss important information, since
c o r e t v a s a 5 6 ( 2 0 1 4 ) 4 6 3 – 4 7 0 e465for example in the EVEREST trial only 33.2% of patients had
aldosterone levels above 160 ng/dL [11], and increased mortal-
ity was also observed in lower aldosterone quartiles.
We studied aldosterone (ng/dL) and renin (pg/mL) regarding
the following covariates: age; sex; diabetes mellitus (DM);
ischemic HF; EF (%); atrial ﬁbrillation (AF); systolic blood
pressure (SBP); intravenous (IV) furosemide dose; proportion of
patients with IV furosemide at day 3; proportion of patients on
angiotensin converting enzyme inhibitors (ACEi), angiotensin
receptor blockers (ARBs), beta-blockers (BBs), and spironolac-
tone; pCr (mg/dL), pUr (mg/dL), NTproBNP (pg/mL), hsTnT (ng/
mL), sodium (mmol/L), potassium (mmol/L), uNa/K ratio,
proteinuria (g/g), red-cell distribution width (RDW), HgB (g/
dL), and length of stay.
Statistical analysis
Normally distributed continuous variables are expressed as
mean  standard deviation (SD), and skewed distributions are
presented as median [interquartile range, IQR].Table 1 – Population characteristics, laboratory results, and sp
Age (years) 76.0  10.88
Male sex (%) 39
DM (%) 45
Ischemic HF (%) 50
EF < 40 (%) 32
AF (%) 59
RDW (%) 15.20 [14.40–16.0]
Hemoglobin (g/dL) 12.43  2.07
Length of stay (days) 8.86  3.36
Day 1 
Spironolactone (%) 50 
Spironolactone dose (mg) 94.50  23.31 
ACEi/ARB (%) 44 
ACEi/ARB dose (mg) 4.79  3.01 
Beta-blocker (%) 37 
Beta-blocker dose (mg) 4.06  1.77 
Furosemide IV dose (mg) 81.08  22.08 
Oral furosemide (%) 0 
Oral furosemide dose (mg) 0 
SBP (mmHg) 139.79  25.86 
Sodium (mmol/L) 140.54  4.38 
Potassium (mmol/L) 4.03  0.51 
Plasma creatinine (mg/dL) 1.04 [0.89–1.31] 
Plasma urea (mg/dL) 55.21  20.84 
Proteinuria (g/g) 0.289 [0.188–0.629] 
NTproBNP (pg/mL) 2750 [1672–6032] 
uNa/K ratio 3.04 [1.52–5.76] 
Renin (pg/mL) 4.35 [2.30–10.78] 
Aldosterone (ng/dL) 35.0 [12.0–92.5] 
hsTnT (ng/mL) 0.033 [0.193–0.050] 
Continuous variables are presented as mean value  standard deviation 
variables are presented as absolute number (%), p value.
Note: Day 1 analysis was collected before the spironolactone administrat
DM, diabetes mellitus; EF, left ventricular ejection fraction; HF, heart fa
angiotensin converting enzyme inhibitors/angiotensin receptor blockers
natriuretic peptide; uNa/K, urinary sodium to potassium; hsTnT, high se
Bold means p value < 0.05.
a Nonparametric paired sample test.
b Chi-square test.Because of the positively skewed distributions of aldoste-
rone, renin, pCr, proteinuria, RDW, NTproBNP, hsTnT, and
uNa/K ratio, these variables were log transformed for analysis.
Categorical variables are expressed in proportions (%).
Comparison between the groups was performed using
parametric, nonparametric tests, or chi-square tests, as
appropriate. Signiﬁcant association was deﬁned by a proba-
bility ( p) value ≤0.05.
Statistical analysis was performed using SPSS software
(version 19, Chicago, IL, USA).
Results
Baseline characteristics, medications, and lab results
Mean  SD age of the 100 patients admitted due to ADHF was
76.0  10.9 years. Thirty-nine patients were male; 50 patients
had documented ischemic heart disease (IHD); 45 had DM; 59
had AF; 32 patients had EF <40%.ironolactone dose at admission day (day 1) and day 3.
Day 3 p value
50 1b
62.74  24.33 <0.001
61 0.069b
3.79  2.63 0.034
57 0.143b
3.19  1.54 0.026
67.57  25.54 0.001
63 <0.001b
74.60  28.10 <0.001
121.97  16.20 <0.001
140.68  3.95 0.718
4.04  0.54 0.950
1.06 [0.85–1.40] 0.082a
62.3  25.47 0.001
0.299 [0.160–0.097] 0.045a
1835 [902–3837] <0.001a
2.80 [1.50–4.78] 0.341a
5.34 [3.14–16.30] 0.011a
67.0 [21.3–125.0] 0.002a
0.030 [0.018–0.051] 0.039a
[SD], p value or median [interquartile range, IQR], p value. Categorical
ion.
ilure; AF, atrial ﬁbrillation; SBP, systolic blood pressure; ACEi/ARBs,
; RDW, red cell distribution width; NTproBNP, N-terminal pro-brain
nsitivity troponin T.
Fig. 1 – Comparison of urinary sodium to potassium ratio
according to renin and aldosterone levels at admission.
Renin = log renin; aldosterone = log aldosterone; uNa/
K = urinary sodium to potassium. Patients with higher
renin and aldosterone levels at admission had lower
urinary sodium to potassium ratios.
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aldosterone, and hsTnT decreased from admission to day 3
(all, p < 0.05). The proportion of patients taking ACEi/ARB and
BB did not differ between admission and day 3.
Patient characteristics, lab results at admission day, and
hospital length of stay are shown in Table 1.
Comparison between normal and high renin values at
admission
A higher proportion of patients with renin levels above 16.5 pg/
mL had AF (52.5% vs. 85%, p = 0.008). Log RDW, log renin, and
hospital length of stay were higher in patients with renin
levels above the cutoff (1.18  0.03 vs.1.21  0.06, p = 0.004 and
8.36  3.21 vs. 10.85  3.25, p = 0.006, respectively) (Table 2). On
the other hand, uNa/K ratio was lower in patients with higher
renin levels (0.50  0.38 vs. 0.22  0.31, p = 0.003) (Table 2 and
Fig. 1).
Comparison between normal and high aldosterone values at
admission
Patients with lower aldosterone levels were more often male
(45.5% vs. 17.4%, p = 0.015). Higher levels of serum potassium,
log proteinuria, log RDW, log NTproBNP, log aldosterone, and
plasma urea were observed in patients with aldosterone levels
above the 100 ng/dL cutoff (all p < 0.05) (Table 2). Similar to the
renin ﬁndings, a lower uNa/K ratio was observed in patients
with higher aldosterone levels (0.49  0.37 vs. 0.29  0.37,
p = 0.026) (Table 2 and Fig. 1).Table 2 – Comparison between normal and high renin and ald
Renin <16.5
(n = 80)
Renin ≥16.5
(n = 20)
p va
Age 75.99  10.33 76.05  13.13 0.9
Male sex, no. (%) 30 (37.5) 9 (45) 0.5
DM, no. (%) 38 (47.5) 7 (35) 0.3
EF <40%, no. (%) 26 (32.5) 5 (25) 0.5
Ischemic HF, no. (%) 37 (46.3) 13 (65) 0.1
AF, no. (%) 42 (52.5) 17 (85) 0.0
SBP 140.93  26.08 135.25  25.11 0.3
Beta-blocker, no. (%) 31 (38.8) 5 (25) 0.2
ACEi/ARB, no. (%) 34 (42.5) 8 (40) 0.8
Sodium 140.75  4.41 139.70  4.26 0.3
Potassium 4.05  0.50 3.98  0.55 0.5
Log creatinine 0.02  0.11 0.02  0.14 0.8
Log proteinuria 0.44  0.40 0.45  0.47 0.9
Log RDW 1.18  0.03 1.21  0.06 0.0
Log NTproBNP 3.49  0.45 3.41  0.35 0.4
Log uNa/K ratio 0.50  0.38 0.22  0.31 0.0
Log aldosterone 1.53  0.43 1.70  0.49 0.1
Log renin 0.52  0.33 1.46  0.22 <0.0
Log hsTnT 1.47  0.39 1.47  0.33 0.9
Urea 53.78  19.68 60.95  24.68 0.1
Hemoglobin 12.50  1.98 12.16  2.44 0.5
Log length of stay 0.89  0.17 1.01  0.15 0.0
DM, diabetes mellitus; EF, left ventricular ejection fraction; HF, heart fa
angiotensin converting enzyme inhibitors/angiotensin receptor blockers
natriuretic peptide; uNa/K, urinary sodium to potassium; hsTnT, high se
Bold means p value < 0.05.Comparison between normal and high renin values at day 3
A higher proportion of patients with renin levels above 16.5 pg/
mL were observed in subjects submitted to spironolactone
treatment (44.7% vs. 66.7%, p = 0.050). Log renin and aldoste-
rone levels were higher in patients with renin levels above the
cutoff point (both p < 0.05). Contrary to the ﬁndings at
admission, uNa/K ratio did not differ between the groups
(Table 3).osterone values at admission.
lue Aldosterone <100
(n = 77)
Aldosterone ≥100
(n = 23)
p value
82 74.91  10.70 76.65  10.88 0.066
39 35 (45.5) 4 (17.4) 0.015
15 34 (44.2) 11 (47.8) 0.756
17 25 (32.5) 6 (26.1) 0.562
34 37 (48.1) 13 (58.5) 0.476
08 44 (57.1) 15 (65.2) 0.490
83 140.84  26.72 136.26  22.94 0.459
52 27 (35.1) 9 (39.1) 0.722
39 32 (41.6) 10 (43.5) 0.870
40 140.84  4.54 139.52  3.69 0.205
86 3.97  0.47 4.24  0.57 0.023
88 0.02  0.12 0.04  0.11 0.495
62 0.51  0.39 0.23  0.42 0.008
04 1.18  0.04 1.20  0.04 0.047
44 3.42  0.41 3.67  0.47 0.014
03 0.49  0.37 0.29  0.37 0.026
35 1.39  0.34 2.15  0.12 <0.001
01 0.69  0.48 0.78  0.50 0.402
95 1.47  0.39 1.47  0.34 0.988
70 52.44  20.52 64.48  19.60 0.014
12 12.39  2.06 12.59  2.17 0.689
03 0.91  0.16 0.91  0.19 0.958
ilure; AF, atrial ﬁbrillation; SBP, systolic blood pressure; ACEi/ARBs,
; RDW, red cell distribution width; NTproBNP, N-terminal pro-brain
nsitivity troponin T.
Table 3 – Comparison between normal and high renin and aldosterone values at day 3.
Renin <16.5
(n = 76)
Renin ≥16.5
(n = 24)
p value Aldosterone <100
(n = 66)
Aldosterone ≥100
(n = 34)
p value
Age 76.58  9.61 74.17  14.25 0.346 78.02  9.28 72.09  12.70 0.009
Male sex, no. (%) 28 (36.8) 11 (45.8) 0.431 25 (37.9) 14 (41.2) 0.749
DM, no. (%) 37 (48.7) 8 (33.3) 0.188 29 (43.9) 16 (47.1) 0.766
EF <40%, no. (%) 22 (28.9) 9 (37.5) 0.430 18 (27.3) 13 (38.2) 0.262
Ischemic HF, no. (%) 36 (47.4) 14 (58.3) 0.241 30 (45.5) 20 (68.8) 0.205
AF, no. (%) 43 (56.6) 16 (66.7) 0.264 42 (63.6) 17 (50) 0.189
SBP 123.55  16.73 116.96  13.52 0.082 122.55 15.76 120.85 17.20 0.623
Beta-blocker, no. (%) 46 (60.5) 11 (45.8) 0.205 38 (57.6) 19 (55.9) 0.871
ACEi/ARB, no. (%) 48 (63.2) 13 (54.2) 0.431 41 (62.1) 20 (58.8) 0.749
IV furosemide, no. (%) 27 (35.5) 10 (41.7) 0.587 25 (37.9) 12 (35.4) 0.800
Spironolactone, no. (%) 34 (44.7) 16 (66.7) 0.050 28 (56) 22 (64.7) 0.035
Spironolactone dose 63.89  24.96 60.29  23.48 0.620 60.00  23.31 66.30  25.68 0.355
Sodium 141.11  3.85 139.33  4.05 0.055 141.12 4.33 139.82  2.96 0.121
Potassium 4.01  0.56 4.14  0.49 0.299 4.00 0.50 4.10 0.61 0.402
Log creatinine 0.03  0.14 0.05  0.16 0.675 0.02  0.14 0.07  0.14 0.058
Log proteinuria 0.46  0.38 0.59  0.31 0.132 0.49  0.35 0.49  0.41 0.955
Log RDW 1.18  0.03 1.21  0.06 0.007 1.19  0.04 1.18  0.04 0.658
Log NTproBNP 3.27  0.50 3.29  0.51 0.881 3.28  0.49 3.24  0.52 0.679
Log uNa/K ratio 0.42  0.40 0.34  0.37 0.378 0.44  0.38 0.31  0.40 0.120
Log aldosterone 1.64  0.45 1.94  0.51 0.007 1.47  0.38 2.21  0.19 <0.001
Log renin 0.59  0.34 1.52  0.25 <0.001 0.69  0.45 1.07  0.54 <0.001
Log hsTnT 1.51  0.33 1.52  0.42 0.838 1.51  0.33 1.51  0.39 0.942
Urea 60.86  25.20 66.92  26.32 0.312 60.70  26.83 65.44  22.64 0.380
Hemoglobin 12.52  2.11 12.16  1.96 0.465 12.38  2.11 12.53  2.03 0.728
Log length of stay 0.89  0.17 0.99  0.13 0.008 0.89  0.18 0.96  0.13 0.043
DM, diabetes mellitus; EF, left ventricular ejection fraction; HF, heart failure; AF, atrial ﬁbrillation; SBP, systolic blood pressure; ACEi/ARBs,
angiotensin converting enzyme inhibitors/angiotensin receptor blockers; RDW, red cell distribution width; NTproBNP, N-terminal pro-brain
natriuretic peptide; uNa/K, urinary sodium to potassium; hsTnT, high sensitivity troponin T.
Bold means p value < 0.05.
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day 3
Patients with lower aldosterone levels were older (78.02  9.28
vs. 72.09  12.70, p = 0.009). Similar to the ﬁndings described
for renin at day 3, a higher proportion of patients with
aldosterone levels above 100 ng/dL were observed in subjects
submitted to spironolactone treatment (56% vs. 64.7%,
p = 0.035). Log renin and aldosterone were also higher in this
group of patients (both p < 0.05), and uNa/K ratio did not differ
between the groups (Table 3).
Spironolactone inﬂuence in renin and aldosterone levels
After three days of spironolactone administration the propor-
tion of patients with renin and aldosterone levels above the
cutoff had a signiﬁcant increase (from 24% to 32%, p = 0.003, and
from 16% to 44%, p < 0.001, respectively) (Table 4 and Fig. 2).Table 4 – Comparison of renin and aldosterone levels at admis
Day 1 
Spironolactone Control 
Renin >16.5, no. (%) 12 (24) 8 (16) 
Aldosterone >100, no. (%) 8 (16) 15 (30) 
Note: Day 1 analysis was performed before the spironolactone administr
Bold means p value < 0.05.Discussion
The main results of our pilot study suggest that in patients
submitted to spironolactone treatment the levels of renin and
aldosterone increase. Higher levels of renin and aldosterone
were not observed with the use of drugs other than
spironolactone (p.e. ACEi/ARBs, BB, or loop diuretics).
At admission higher renin and aldosterone levels were
associated with lower urinary Na/K ratio levels, and these
ﬁndings were not reproduced when the patients were
submitted to MRA. In addition, higher levels of renin and
aldosterone at admission were associated with higher RDW.
Higher renin was associated with longer length of stay, and
higher aldosterone with higher NTproBNP.
Baseline aldosterone blood levels measured in chronic HF
patients with LVEF <40% during the ﬁrst days after admission
for AHF were signiﬁcantly correlated with higher mortality andsion and day 3 within spironolactone and control groups.
Day 3
p value Spironolactone Control p value
0.317 16 (32) 8 (16) 0.050
0.096 22 (44) 12 (24) 0.035
ation.
24
16
32
44
0
10
20
30
40
50
60
Renin > 16,5 Aldosterone > 100
Before Spironolactone Aer Spironolactone
Fig. 2 – Comparison of renin and aldosterone levels before
and after the spironolactone treatment. Results are
presented in percentage (%) of total. Renin is expressed in
pg/mL and aldosterone in ng/dL. The proportion of patients
with increased levels of renin and aldosterone is
significantly higher in patients submitted to spironolactone
treatment. The proportion of patients with renin levels
above 16.5 pg/mL increases from 24% before the
spironolactone administration to 32% after spironolactone
administration, p value = 0.003. The proportion of patients
with aldosterone levels above 100 ng/dL increases from
16% before the spironolactone administration to 44% after
spironolactone administration, p value <0.001.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 6 3 – e 4 7 0e468rehospitalization for HF [11]. Aldosterone levels were found to
increase substantially during hospitalization and remain
elevated after discharge, despite excellent background RAAS
inhibitor therapy. The association between higher aldosterone
levels and worse outcome remains positive, although weaker,
when considering discharge aldosterone measurement [11].
Based on these ﬁndings the authors of this trial suggest that
further neurohormonal modulation may be required in order
to improve outcomes. In our interventional trial [12] we
demonstrated that additional MR blockade during the acute
decompensation is not associated with electrolyte disorders or
kidney dysfunction and probably portends greater congestion
relief, translated into a steep natriuretic peptide decrease. In
this secondary analysis we demonstrated that renin and
aldosterone levels are increased by spironolactone and not
by ACEi/ARB, beta-blockers, or diuretics, as shown by the
signiﬁcant higher proportion of patients with levels of renin
and aldosterone above the cutoff within spironolactone group,
and not in patients under ACEi/ARB, beta-blockers, or
diuretics. Furthermore, blood pressure and electrolytes are
not likely to inﬂuence the observed variation in these
hormones. These ﬁndings are concordant with previous
reports in which the physiological elevation in plasma renin
activity (PRA) and aldosterone were demonstrated in response
to eplerenone and spironolactone treatment [13–17]. A previ-
ous study reported an increase in both PRA and aldosterone
after eplerenone treatment for 10 days in dogs [18]. Similarly,
in humans, eplerenone resulted in elevations in serum
aldosterone and PRA when administered for 8 weeks in
addition to a ﬁxed dose of an ACEi in mildly hypertensivepatients [16]. A larger study reported an increase in serum
aldosterone with eplerenone treatment that was dose respon-
sive [19]. Furthermore, in patients with resistant hypertension
an inverse correlation between blood pressure and serum
aldosterone was demonstrated after treatment with epler-
enone for 12 weeks [20], and another study demonstrated a
time-dependent aldosterone increased in response to epler-
enone [13]. The most robust explanation to this ﬁnding results
from the demonstration that the main physiologic regulators
of aldosterone synthase are angiotensin II and potassium [21].
Thus, increases in serum potassium and angiotensin II
resulting from a decreased sodium and increased potassium
reabsorption in the proximal tubules would lead to an
upregulation of aldosterone synthase, consequently increas-
ing the aldosterone levels. Another potential explanation for
the increase in aldosterone is a direct regulation of aldosterone
synthase by mineralocorticoid receptor [13]. Our results can be
very interesting and innovative, since MRA can probably
improve outcomes in ADHF and also can increase renin and
aldosterone levels; therefore, higher levels of aldosterone may
not hold place for prognostic purposes when full MRA is
provided. However, further studies are warranted to fully
understand the mechanisms underlying the rise in aldoste-
rone following MRA and the prognostic signiﬁcance of MR
blockade in the decompensated HF setting.
The median aldosterone levels at admission appear higher
than the median values found in previous reports of patients
with acute and chronic heart failure after the widespread use
of ACEi/ARB [4–7,11]. This ﬁnding may be explained by the
lower proportion (only 44%) of the patients on baseline ACEi/
ARB, potentially leading to higher levels of renin and
aldosterone [7,22], similar to the levels found before the
widespread use of the RAAS inhibitors [6,23].
In the present study, higher levels of renin and aldosterone
at admission were associated with higher RDW and lower
urinary Na/K ratio levels. Additionally, higher aldosterone
levels alone were associated with higher NTproBNP and higher
levels of renin alone were associated with longer length of
stay. Despite these side ﬁndings do not compose the bulk of
our study, we think they deserve a brief discussion.
Higher levels of renin and aldosterone at admission were
associated with higher RDW. RDW is a percentual measure of
the variability in the size of circulating erythrocytes [24].
Disorders related to ineffective erythropoiesis or increased
destruction cause greater heterogeneity in size and a higher
RDW [25]. In patients with ADHF higher RDW have been
associated with slower diuretic response [26] and increased
long-term mortality [27]. The relationship between elevated
hormone levels and poor outcome can reﬂect the possibility
that hormonal activation is not only serving as a marker for the
severity of the disease, but is also contributing to progression
of HF [5].
Higher aldosterone levels were associated with higher
NTproBNP. To the best of our knowledge, this is the ﬁrst study
to demonstrate a signiﬁcant association between increased
aldosterone levels and increased natriuretic peptides. Howev-
er, previous studies demonstrated that the aldosterone
receptor antagonism with spironolactone induces more
noticeable decreases in plasma BNP levels than placebo or
no spironolactone [12,28], suggesting that aldosterone may
c o r e t v a s a 5 6 ( 2 0 1 4 ) 4 6 3 – 4 7 0 e469have an important role in the process of left ventricular
remodeling [28].
As described above, increased neurohormonal activation
is associated with worse outcome [11]. Our study was
underpowered to detect major events, but length of stay
could serve as a potential indirect severity measure. However,
length of stay may be affected by comorbidities other than HF
and in-hospital complications. Despite the association of
higher levels of renin at admission and longer length of stay
may appear to be an attractive result, the lack of correspon-
dence in aldosterone and the bias inherent to length of stay
make this result less appealing and with dubious external
validity.
Activation of the RAAS causes reabsorption of Na+ and the
excretion of K+ in various epithelia such as the distal nephron
[29]. Higher renin and aldosterone levels at admission were
also associated with lower urinary Na/K ratio levels; these
ﬁndings were not reproduced when patients were submitted
to MRA. These observations are consistent with the RAAS
effects on distal nephron, i.e. higher levels of renin and
aldosterone lead to higher Na+ reabsorption and K+ excretion,
decreasing uNa/K ratio. On the other hand, in the group of
patients submitted to spironolactone treatment, uNa/K ratio
increased probably reﬂecting the MRA effect. These dynamic
changes suggest that uNa/K ratio can serve as a potential
biomarker for MRA [13].
Our study has several limitations that should be noticed.
First, it was a single center of a small sample size study.
Second, no randomization or concealed allocation was
performed; therefore, we cannot exclude a selection bias
potentially affecting the external validity of our results,
particularly on outcome results such as length of stay;
however, we included internal control variables such as renin,
aldosterone, and NTproBNP that are less likely to be affected
by bias and appear to be consistent with previous reports.
Third, this study was performed post hoc; therefore, it is
subject to the potential biases inherent to analyses of
observational data. Fourth, baseline blood samples were
collected in the ﬁrst 24 h after the admission and before the
spironolactone administration, but most patients had already
received diuretics and/or vasodilators; as a consequence, renin
and aldosterone admission levels may not reﬂect the real
decompensation values. Fifth, high aldosterone cutoff was
lowered to 100 ng/dL to increase test sensitivity; despite losing
speciﬁcity we were able to detect a higher proportion of
patients with aldosterone increments. Finally, our inclusion
criteria by restricting the enrollment of patients with hyper-
kalemia, impaired renal function, and severe valvular disease
may be responsible for the good treatment response of our
population and therefore limit the external validity of our
conclusions.
Conclusion
Higher levels of aldosterone are associated with higher
mortality risk in ADHF patients. High-dose spironolactone
added to standard ADHF therapy induces an additional
increase in renin and aldosterone levels. Whether higher
levels of renin and aldosterone due to the reactive response tofull MRA still have prognostic value requires further investi-
gation.
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